N-羟基-4-甲基-1-哌嗪甲脒 | 721450-28-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: N-羟基-4-甲基-1-哌嗪甲脒
• 英文名称: 4-methylpiperazine-amidoxime
• 英文别名: N'-hydroxy-4-methylpiperazine-1-carboximidamide
• CAS: 721450-28-8
• 化学式: C₆H₁₄N₄O
• 分子量: 158.203
• InChiKey: JXVYVKVMVOGMAX-UHFFFAOYSA-N

物化性质

• 沸点：
  246.4±50.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  65.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-硝基-4,5-二苄氧基苯甲酸 、 N-羟基-4-甲基-1-哌嗪甲脒 在 N,N'-羰基二咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以545 mg的产率得到
  参考文献：
  名称：

  Discovery of a Long-Acting, Peripherally Selective Inhibitor of Catechol-O-methyltransferase

  摘要：

  Novel nitrocatechol-substituted heterocycles were designed and evaluated for their ability to inhibit catechol-O-methyltransferase (COMT). Replacement of the pyrazole core of the initial hit 4 with a 1,2,4-oxadiazole ring resulted in a series of compounds endowed with longer duration of COMT inhibition. Incorporation of a pyridine N-oxide residue at position 3 of the 1,2,4-oxadiazole ring led to analogue 37f, which was found to possess activity comparable to entacapone and lower toxicity in comparison to tolcapone. Lead structure 37f was systematically modified in order to improve selectivity and duration of COMT inhibition as well as to minimize toxicity. Oxadiazole 37d (2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide (BIA 9-1067)) was identified as a long-acting, purely peripheral inhibitor, which is currently under clinical evaluation as an adjunct to L-Dopa therapy of Parkinson's disease.

  DOI：

  10.1021/jm1001524

文献信息

• 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：Cytovia, Inc.

  公开号：US20040127521A1

  公开（公告）日：2004-07-01

  Disclosed are 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: 1 wherein Ar 1 , R 2 , A, B and D are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  揭示了3,5-二取代-[1,2,4]-噁二唑及其类似物，由式I所表示：其中Ar1、R2、A、B和D在此处定义。本发明涉及发现具有式I的化合物是半胱氨酸蛋白酶激活剂和凋亡诱导剂。因此，本发明的半胱氨酸蛋白酶激活剂和凋亡诱导剂可用于诱导在各种临床病况中发生细胞死亡的情况，其中出现了异常细胞的不受控制的生长和扩散。
• 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use of thereof
  申请人：Cai Xiong Sui

  公开号：US20070112003A1

  公开（公告）日：2007-05-17

  Disclosed are 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: wherein Ar 1 , R 2 , A, B and D are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及3,5-二取代-[1,2,4]-噁二唑及其类似物，由式I表示：其中Ar1、R2、A、B和D在此定义。本发明涉及发现具有式I的化合物是caspase的激活剂和凋亡诱导剂。因此，本发明的caspase激活剂和凋亡诱导剂可用于诱导在不受控制的异常细胞生长和扩散的各种临床状况中的细胞死亡。
• 3,5-DISUBSTITUTED- 1,2,4 -OXADIAZOLES AND ANALOGS AS AC TIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
  申请人：Cytovia, Inc.

  公开号：EP1581213A1

  公开（公告）日：2005-10-05
• EP1581213A4
  申请人：——

  公开号：EP1581213A4

  公开（公告）日：2008-11-19
• US7144876B2
  申请人：——

  公开号：US7144876B2

  公开（公告）日：2006-12-05